Skip to main content
BMRN
NASDAQ Life Sciences

BioMarin Quantifies Alesta Acquisition Charges: ~$320M Pre-Tax Hit, ~$1.55 EPS Drag for 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$56.22
Mkt Cap
$10.883B
52W Low
$49.259
52W High
$70.98
52W Position info
14% above low
Off High info
21% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

BMRN is trading near its 52-week low of $49.259 (14% above the low) on elevated volume (1.9× avg).

Summary

BioMarin quantified the financial impact of its Alesta Therapeutics acquisition: ~$283M Q3 IPR&D charge, ~$320M full-year pre-tax charges, and ~$1.55 EPS drag for 2026. The Alesta acquisition closed in early September. Updated guidance will come with Q3 results.

Updated with a Dow Jones Newswires report · What changed

Updates

  1. · Dow Jones Newswires — BioMarin expects $283 million in pre-tax charges in Q3 from its Alesta acquisition, closed in early September.


Key Events · Earnings and Guidance · BMRN

  • Updated · · Dow Jones Newswires

    Alesta Acquisition Charges Quantified

    BioMarin expects ~$283M pre-tax acquired IPR&D expense in Q3 2026 and ~$320M total pre-tax charges for full-year 2026 related to the Alesta Therapeutics acquisition, which closed in early September.

  • EPS Impact Disclosed

    The charges represent an unfavorable impact of ~$1.50 to Q3 diluted EPS and ~$1.55 to full-year 2026 diluted EPS, on both GAAP and non-GAAP bases.

  • Prior Guidance Did Not Include Deal

    BioMarin's full-year 2026 guidance announced August 6, 2026 did not reflect the Alesta acquisition; updated guidance will be provided with Q3 2026 results.

  • Preliminary Estimates Subject to Change

    Q3 results are not finalized and actual results may differ from these preliminary estimates.


Analysis · BMRN · Life Sciences

BioMarin disclosed that its Alesta Therapeutics acquisition, which closed in early September, will generate approximately $283 million in acquired in-process R&D expense in Q3 2026 and roughly $320 million in total pre-tax charges for the full year, translating to an unfavorable impact of about $1.50 per share in Q3 and $1.55 per share for 2026 on both GAAP and non-GAAP diluted EPS. The company's prior full-year guidance did not include these charges, so investors should expect a downward revision when Q3 results are reported. This is a material quantification of a previously announced deal, not a new acquisition.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BMRN was trading at $56.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $49.26 to $70.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BMRN - Latest Insights

BMRN
Nov 03, 2026, 4:34 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $55.66
Real-time Price: $56.12 info
Change: +$0.460 (+0.83%) info
Market Cap: $10.87B info
BMRN
Nov 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $54.79
Real-time Price: $56.12 info
Change: +$1.33 (+2%) info
Market Cap: $10.87B info
BMRN
Nov 02, 2026, 4:03 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $57.44
Real-time Price: $56.12 info
Change: -$1.32 (-2%) info
Market Cap: $10.87B info
BMRN
Oct 29, 2026, 8:57 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $56.40
Real-time Price: $56.12 info
Change: -$0.280 (-0.50%) info
Market Cap: $10.87B info
BMRN
Aug 31, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.95
Real-time Price: $56.12 info
Change: -$11.83 (-17%) info
Market Cap: $10.87B info